-DOCSTART- -X- O
Within -X- _ O
the -X- _ O
last -X- _ O
decade -X- _ O
new -X- _ O
technologies -X- _ O
have -X- _ O
been -X- _ O
developed -X- _ O
and -X- _ O
implemented -X- _ O
which -X- _ O
employ -X- _ O
light -X- _ B-Intervention
, -X- _ I-Intervention
often -X- _ I-Intervention
in -X- _ I-Intervention
the -X- _ I-Intervention
presence -X- _ I-Intervention
of -X- _ I-Intervention
a -X- _ I-Intervention
photosensitizer -X- _ I-Intervention
, -X- _ I-Intervention
to -X- _ I-Intervention
inactivate -X- _ I-Intervention
pathogens -X- _ I-Intervention
that -X- _ O
reside -X- _ O
in -X- _ O
human -X- _ B-Patient
blood -X- _ I-Patient
products -X- _ I-Patient
for -X- _ I-Patient
the -X- _ I-Patient
purpose -X- _ I-Patient
of -X- _ I-Patient
transfusion. -X- _ I-Patient
These -X- _ O
pathogen -X- _ O
reduction -X- _ O
technologies -X- _ O
attempt -X- _ O
to -X- _ O
find -X- _ O
the -X- _ O
proper -X- _ O
balance -X- _ O
between -X- _ O
pathogen -X- _ B-Outcome
kill -X- _ I-Outcome
and -X- _ I-Outcome
cell -X- _ I-Outcome
quality. -X- _ I-Outcome
Each -X- _ O
system -X- _ O
utilizes -X- _ O
various -X- _ O
chemistries -X- _ O
that -X- _ O
not -X- _ O
only -X- _ O
impact -X- _ O
which -X- _ O
pathogens -X- _ O
they -X- _ O
can -X- _ O
inactivate -X- _ O
and -X- _ O
how -X- _ O
, -X- _ O
but -X- _ O
also -X- _ O
how -X- _ O
the -X- _ O
treatments -X- _ O
affect -X- _ O
the -X- _ O
plasma -X- _ O
and -X- _ O
cellular -X- _ O
proteins -X- _ O
and -X- _ O
to -X- _ O
what -X- _ O
degree. -X- _ O
This -X- _ O
paper -X- _ O
aims -X- _ O
to -X- _ O
present -X- _ O
the -X- _ O
various -X- _ O
chemical -X- _ O
mechanisms -X- _ O
for -X- _ O
pathogen -X- _ O
reduction -X- _ O
in -X- _ O
transfusion -X- _ O
medicine -X- _ O
that -X- _ O
are -X- _ O
currently -X- _ O
practiced -X- _ O
or -X- _ O
in -X- _ O
development -X- _ O
. -X- _ O

